Home / News and media / Stock exchange releases / Archive / 2009

2009

Dec 4th 2009 5:04 PM Stock Exchange Release

Orion clarifies information emanating from Capital Markets Day
Nov 27th 2009 9:00 AM Stock Exchange Release

100,000 Orion A-shares converted into B-shares
Oct 26th 2009 12:01 PM Stock Exchange Release

Orion Group Interim Report January-September 2009
Oct 26th 2009 11:45 AM Stock Exchange Release

Orion Corporation's publication schedules for financial reporting in 2010
Oct 21st 2009 5:15 PM Stock Exchange Release

Orion withdraws US application for extending the indication of Stalevo®
Oct 6th 2009 2:00 PM Stock Exchange Release

Orion invites analysts and media to Q3 news conference on Monday 26 October 2009
Sep 21st 2009 3:45 PM Stock Exchange Release

Composition of the Nomination Committee of Orion Corporation
Sep 4th 2009 9:50 PM Stock Exchange Release

Orion and Hospira,Inc. sue Sandoz companies in the U.S. to enforce their U.S. Patents covering the proprietary drug Precedex®
Aug 7th 2009 3:35 PM Stock Exchange Release

Orion: Correction to English version of Interim Report 1-6/2009
Aug 7th 2009 12:01 PM Stock Exchange Release

Orion Group Interim Report January-June 2009
Jul 31st 2009 2:30 PM Stock Exchange Release

Orion comments on ANDA filed by Sandoz Inc. for a generic version of Orion's proprietary drug Precedex® (dexmedetomidine hydrochloride 100 mcg base/ml ) in the United States
Jun 10th 2009 11:30 AM Stock Exchange Release

Orion invites analysts and media to Q2 news conference on Friday 7 August 2009
May 6th 2009 9:30 AM Stock Exchange Release

Orion reacquires rights for i.v. levosimendan (Simdax®)
Apr 29th 2009 10:42 AM Stock Exchange Release

Orion and Wockhardt settle patent dispute
Apr 27th 2009 12:01 PM Stock Exchange Release

Orion Group Interim Report 1-3/2009
Apr 20th 2009 1:30 PM Stock Exchange Release

Orion invites to a Q1 news conference on Monday 27 April 2009
Apr 14th 2009 9:51 AM Stock Exchange Release

Amendments to Orion's Articles of Association entered in the Trade Register
Mar 23rd 2009 7:20 PM Stock Exchange Release

Orion Corporation: Jukka Ylppö Vice Chairman of the Board of Directors. Compositions of Board committees
Mar 23rd 2009 7:01 PM Stock Exchange Release

Orion Corporation: Decisions by the AGM on 23 March 2009
Mar 6th 2009 1:59 PM Stock Exchange Release

Orion withdraws EU application for extending the indication of Stalevo®
Mar 5th 2009 6:47 PM Stock Exchange Release

Orion Corporation: Transfer of 44,806 own B-shares
Mar 4th 2009 10:01 AM Stock Exchange Release

Orion Group Annual Report 2008 published
Feb 24th 2009 8:30 AM Stock Exchange Release

Orion: Primary objective of STRIDE-PD study was not achieved
Feb 6th 2009 12:10 PM Stock Exchange Release

Matters to be handled at the AGM of Orion Corporation on 23 March 2009
Feb 6th 2009 12:01 PM Stock Exchange Release

Orion Group Financial Review of 2008
Jan 28th 2009 4:56 PM Stock Exchange Release

Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2009 AGM of Orion Corporation
Jan 16th 2009 10:45 AM Stock Exchange Release

Orion: Annual Summary of Stock Exchange Releases and Announcements published in 2008
Jan 15th 2009 8:14 PM Stock Exchange Release

Orion sues Wockhardt USA LLC and Wockhardt Limited in the U.S. to enforce Orion's U.S. Patents covering its proprietary drug Stalevo®
Jan 7th 2009 9:00 AM Stock Exchange Release

Orion's statutory negotiations completed. Personnel to be reduced by about 205 in Finland

2009

Orion clarifies information emanating from Capital Markets Day

100,000 Orion A-shares converted into B-shares

Orion Group Interim Report January-September 2009

Orion Corporation's publication schedules for financial reporting in 2010

Orion withdraws US application for extending the indication of Stalevo®

Orion invites analysts and media to Q3 news conference on Monday 26 October 2009

Composition of the Nomination Committee of Orion Corporation

Orion and Hospira,Inc. sue Sandoz companies in the U.S. to enforce their U.S. Patents covering the proprietary drug Precedex®

Orion: Correction to English version of Interim Report 1-6/2009

Orion Group Interim Report January-June 2009

Orion comments on ANDA filed by Sandoz Inc. for a generic version of Orion's proprietary drug Precedex® (dexmedetomidine hydrochloride 100 mcg base/ml ) in the United States

Orion invites analysts and media to Q2 news conference on Friday 7 August 2009

Orion reacquires rights for i.v. levosimendan (Simdax®)

Orion and Wockhardt settle patent dispute

Orion Group Interim Report 1-3/2009

Orion invites to a Q1 news conference on Monday 27 April 2009

Amendments to Orion's Articles of Association entered in the Trade Register

Orion Corporation: Jukka Ylppö Vice Chairman of the Board of Directors. Compositions of Board committees

Orion Corporation: Decisions by the AGM on 23 March 2009

Orion withdraws EU application for extending the indication of Stalevo®

Orion Corporation: Transfer of 44,806 own B-shares

Orion Group Annual Report 2008 published

Orion: Primary objective of STRIDE-PD study was not achieved

Matters to be handled at the AGM of Orion Corporation on 23 March 2009

Orion Group Financial Review of 2008

Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2009 AGM of Orion Corporation

Orion: Annual Summary of Stock Exchange Releases and Announcements published in 2008

Orion sues Wockhardt USA LLC and Wockhardt Limited in the U.S. to enforce Orion's U.S. Patents covering its proprietary drug Stalevo®

Orion's statutory negotiations completed. Personnel to be reduced by about 205 in Finland

Archive

2012

2011

2010

2009

2008

2007

2006